News & Updates
Read the latest clinical, scientific, corporate, commercial, and event updates from TaiMed Biologics.
2026/07/08
TaiMed Biologics (4147) invited to participate in the TPEx–Fubon Securities Biotechnology Industry Forum To Showcase Long-Acting Biologics Pipeline and Global Commercialization Strategy
2026/07/06
TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan
2026/06/17
TaiMed Advances Long-Acting HIV Therapy Into Late-Stage Development
2026/06/11
TaiMed Biologics (4147) Announces First Patient in TMB-365/380 Phase 2b Trial Successfully Completes Fourth Dose; Sustained Viral Suppression Remains Consistent with Expectations, Supporting an Optimi
2026/06/01
TaiMed Biologics (4147) Achieves Key Milestone for Trogarzo Launch in Taiwan; Partner Orient Pharma (4120) Secures TFDA Name Approval
2026/05/25
TaiMed Biologics (4147) Holds 2026 Annual Shareholders' Meeting; Successfully Approves Private Placement of Common Shares to Further Advance Global Long-Acting Drug Strategy
2026/05/22
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
2026/04/13
TaiMed Biologics (4147) Board Approves Private Placement to Bring in Strategic Investors，Accelerating Global Licensing of Innovative Drugs and Aligning with International Capital Markets
2026/04/10
TaiMed Biologics (4147) CEO Dr. Jimmy Chang Invited to Attend the “19th QIC CEO Week” in Singapore, Engaging with Leading Global Institutional Investors
2026/04/07
TaiMed Biologics (4147) Trogarzo® Qualifies for Zero Tariff Treatment Under U.S. Section 232 Policy with Orphan Drug Designation and Friend-Shoring Supply Chain Advantage
2026/04/07
TaiMed Biologics (4147) TMB-365/380 Phase 2b Enrollment Surpasses 80%, with Peak Annual Sales Potential of Up to US$4 Billion
2026/03/26
TaiMed Biologics(4147) TMB-365/380 Impresses at CROI; Global Pharma Initiates Engagement, First Patient to Receive Third Dose in April
2026/03/23
TaiMed Biologics’TMB-365/380 Advances Ahead of Schedule in Phase 2b; World's Only“No-Screening”Advantage Attracts Strong Global Licensing Interest
2026/03/19
TaiMed Biologics (TPEX: 4147) Leading the Transformation of HIV Treatment — CEO Dr. Jimmy Chang Unveils Platform Strategy for Precision Immunotherapy
2026/03/13
TaiMed Biologics (TPEX: 4147) Leading the Transformation of HIV Treatment — CEO Dr. Jimmy Chang Unveils Platform Strategy for Precision Immunotherapy